ReviewStem cell research & therapy2013
Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells.
Review in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 112 citations in OpenAlex.
- A transgene-free, human peri-gastrulation embryo model presents trilaminar embryonic disc-, amnion- and yolk sac-like structures.Nature cell biology · 2026Article
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- WNK1 mediates M-CSF-induced macropinocytosis to enforce macrophage lineage fidelity.Nature communications · 2025Article
- In vitro erythropoiesis: the emerging potential of induced pluripotent stem cells (iPSCs).Blood science (Baltimore, Md.) · 2025Review
- ICU patient-on-a-chip emulating orchestration of mast cells and cerebral organoids in neuroinflammation.Communications biology · 2024Article
- Mining of potentially stem cell-related miRNAs in planarians.Molecular biology reports · 2024Review
- Progresses in overcoming the limitations of in vitro erythropoiesis using human induced pluripotent stem cells.Stem cell research & therapy · 2024Review
- The past, present, and future promise of pluripotent stem cells.Journal of immunology and regenerative medicine · 2024Article
- CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.Human genetics · 2023Review
- Article
- Understanding blood development and leukemia using sequencing-based technologies and human cell systems.Frontiers in molecular biosciences · 2023Review
- Current Progress of CAR-NK Therapy in Cancer Treatment.Cancers · 2022Review
- Hypoxia drives hematopoiesis with the enhancement of T lineage through eliciting arterial specification of hematopoietic endothelial progenitors from hESC.Stem cell research & therapy · 2022Article
- Impact of APRF+ in Combination with Autogenous Fibroblasts on Release Growth Factors, Collagen, and Proliferation and Migration of Gingival Fibroblasts: An In Vitro Study.Materials (Basel, Switzerland) · 2022Article
- Maternal obesity and the impact of associated early-life inflammation on long-term health of offspring.Frontiers in cellular and infection microbiology · 2022Review
- Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Application of Organoids in Carcinogenesis Modeling and Tumor Vaccination.Frontiers in oncology · 2022Review
- Advances in the application of mesenchymal stem cells, exosomes, biomimetic materials, and 3D printing in osteoporosis treatment.Cellular & molecular biology letters · 2021Review
- Oxygen as a Master Regulator of Human Pluripotent Stem Cell Function and Metabolism.Journal of personalized medicine · 2021Review
- Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pluripotent stem cells, both embryonic stem cells and induced pluripotent stem cells, are undifferentiated cells that can self-renew and potentially differentiate into all hematopoietic lineages, such as hematopoietic stem cells (HSCs), hematopoietic progenitor cells and mature hematopoietic cells in the presence of a suitable culture system. Establishment of pluripotent stem cells provides a comprehensive model to study early hematopoietic development and has emerged as a powerful research tool to explore regenerative medicine. Nowadays, HSC transplantation and hematopoietic cell transfusion have successfully cured some patients, especially in malignant hematological diseases. Owing to a shortage of donors and a limited number of the cells, hematopoietic cell induction from pluripotent stem cells has been regarded as an alternative source of HSCs and mature hematopoietic cells for intended therapeutic purposes. Pluripotent stem cells are therefore extensively utilized to facilitate better understanding in hematopoietic development by recapitulating embryonic development in vivo, in which efficient strategies can be easily designed and deployed for the generation of hematopoietic lineages in vitro. We hereby review the current progress of hematopoietic cell induction from embryonic stem/induced pluripotent stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.